Review



ds3  (Digitimer North America LLC)


Bioz Verified Symbol Digitimer North America LLC is a verified supplier
Bioz Manufacturer Symbol Digitimer North America LLC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Digitimer North America LLC ds3
    Ds3, supplied by Digitimer North America LLC, used in various techniques. Bioz Stars score: 96/100, based on 3293 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ds3/product/Digitimer North America LLC
    Average 96 stars, based on 3293 article reviews
    ds3 - by Bioz Stars, 2026-06
    96/100 stars

    Images



    Similar Products

    super rapid magnetic stimulator  (Welcony)
    97
    Welcony super rapid magnetic stimulator
    Super Rapid Magnetic Stimulator, supplied by Welcony, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/super rapid magnetic stimulator/product/Welcony
    Average 97 stars, based on 1 article reviews
    super rapid magnetic stimulator - by Bioz Stars, 2026-06
    97/100 stars
    		  Buy from Supplier
    genio implantable stimulator  (Nyxoah S.A)
    90
    Nyxoah S.A genio implantable stimulator
    Genio Implantable Stimulator, supplied by Nyxoah S.A, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/genio implantable stimulator/product/Nyxoah S.A
    Average 90 stars, based on 1 article reviews
    genio implantable stimulator - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ds3  (Digitimer North America LLC)
    96
    Digitimer North America LLC ds3
    Ds3, supplied by Digitimer North America LLC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ds3/product/Digitimer North America LLC
    Average 96 stars, based on 1 article reviews
    ds3 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    isolated current stimulator  (Digitimer North America LLC)
    96
    Digitimer North America LLC isolated current stimulator
    Isolated Current Stimulator, supplied by Digitimer North America LLC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/isolated current stimulator/product/Digitimer North America LLC
    Average 96 stars, based on 1 article reviews
    isolated current stimulator - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    recombinant human macrophage colony  (R&D Systems)
    96
    R&D Systems recombinant human macrophage colony
    Recombinant Human Macrophage Colony, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human macrophage colony/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    recombinant human macrophage colony - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay  (Siemens Healthineers)
    86
    Siemens Healthineers atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay
    Atellica Im Thyroid Stimulating Hormone 3 Ultra Tsh3 Ul Assay, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay/product/Siemens Healthineers
    Average 86 stars, based on 1 article reviews
    atellica im thyroid stimulating hormone 3 ultra tsh3 ul assay - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    r2 stimulator  (Magstim Company)
    90
    Magstim Company r2 stimulator
    R2 Stimulator, supplied by Magstim Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r2 stimulator/product/Magstim Company
    Average 90 stars, based on 1 article reviews
    r2 stimulator - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    direct current low intensity stimulator  (Soterix Medical)
    86
    Soterix Medical direct current low intensity stimulator
    Direct Current Low Intensity Stimulator, supplied by Soterix Medical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/direct current low intensity stimulator/product/Soterix Medical
    Average 86 stars, based on 1 article reviews
    direct current low intensity stimulator - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    subthalamic nucleus deep brain stimulation  (Beijing Tiantan Biological)
    86
    Beijing Tiantan Biological subthalamic nucleus deep brain stimulation
    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent <t>subthalamic</t> nucleus deep brain <t>stimulation</t> (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).
    Subthalamic Nucleus Deep Brain Stimulation, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/subthalamic nucleus deep brain stimulation/product/Beijing Tiantan Biological
    Average 86 stars, based on 1 article reviews
    subthalamic nucleus deep brain stimulation - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Journal: Clinical Interventions in Aging

    Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

    doi: 10.2147/CIA.S600031

    Figure Lengend Snippet: Short-term (1 year) and long-term (3 years) dyskinesia outcomes, other motor outcomes, quality of life, neuropsychological outcomes, and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; A-iii ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv) ), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i ), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

    Techniques: Functional Assay

    Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Journal: Clinical Interventions in Aging

    Article Title: Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson’s Disease: A 3-Year Longitudinal Cohort Study

    doi: 10.2147/CIA.S600031

    Figure Lengend Snippet: Relative changes (%) from baseline to short (1 year) term, baseline to long (3 years) term, and short (1 year) term to long (3 years) term dyskinesia outcomes; other motor outcomes; quality of life; neuropsychological outcomes; and cognitive functions of the included patients (n = 84) with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID) who underwent subthalamic nucleus deep brain stimulation (STN-DBS). ( A ) Dyskinesia outcomes such as UDysRS ( A-i ), time spent with LID (MDS-UPDRS-4.1), hours ( A-ii ), and functional impact of LID (MDS-UPDRS-4.2; ( A-iii) ); ( B ) Other motor outcomes such as MDS-UPDRS-III (off-medicine; ( B-i )), MDS-UPDRS-III (on-medicine; ( B-ii )), MDS-UPDRS-II (daily living, ( B-iii )), MDS-UPDRS-IV (motor complications; ( B-iv )), Hoehn & Yahr (off-medicine; ( B-v )), and LEDD, mg ( B-vi ); ( C ) Quality of life as PDQ-39; ( D ) Neuropsychological outcomes such as MDS-UPDRS-I (nonmotor experiences; ( D-i )), HAM-A ( D-ii ), and HAM-D ( D-iii ); and ( E ) Cognitive function as CMMS ( E-i ) and MoCA ( E-ii ). * P < 0.05 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction); ** P < 0.01 (one-way repeated-measures ANOVA or Friedman test, as appropriate, with post hoc pairwise comparisons adjusted by Bonferroni correction).

    Article Snippet: The flowchart details the selection process for a study on Parkinson's patients with levodopa-induced dyskinesia who received subthalamic nucleus deep brain stimulation at Beijing Tiantan Hospital.

    Techniques: Functional Assay